Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Global Sickle Cell Disease Clinical Trial Pipeline Highlights 2020 - ResearchAndMarkets.com
12:00am, Friday, 29'th May 2020
The
3 Top Pharma Stocks to Buy Right Now
04:25pm, Sunday, 24'th May 2020
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quar
How Global Blood Therapeutics (GBT) Stock Stands Out in a Strong Industry
02:58pm, Friday, 15'th May 2020
Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
GBT Announces Upcoming Data Presentations During Virtual Edition of 25th Annual European Hematology Association Congress
01:05pm, Thursday, 14'th May 2020
The abstracts include a retrospective analysis of data from the landmark STOP 2 study linking higher hemoglobin levels to lower transcranial Doppler (TCD) flow velocity, a predictor of stroke risk in
Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), both subsidiaries of Hitachi Chemical Co., Ltd. (Hit
Edited Transcript of GBT earnings conference call or presentation 6-May-20 8:30pm GMT
02:22pm, Thursday, 07'th May 2020
Q1 2020 Global Blood Therapeutics Inc Earnings Call
GBT Announces New Employment Inducement Grants
12:00pm, Thursday, 07'th May 2020
SOUTH SAN FRANCISCO, Calif., May 07, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2020, the compensation committee of GBT’s board.
Global Blood Therapeutics Reports Q1 Beat, Impressive Oxbryta Sales
09:48am, Thursday, 07'th May 2020
Global Blood Therapeutics (GBT) has reported a solid first quarter earnings beat, with Q1 GAAP EPS of -$1.20 beating the Street forecast by $0.31. Meanwhile revenue of $14.12M easily topped Street
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q1 2020 Results - Earnings Call Transcript
03:26am, Thursday, 07'th May 2020
Global Blood Therapeutics, Inc. (NASDAQ:GBT) Q1 2020 Earnings Conference Call May 6, 2020 04:30 PM ET Company Participants Stephanie Yao - Senior Director of In
Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
12:00am, Thursday, 07'th May 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results f
Global Blood Therapeutics (GBT) Reports Q1 Loss, Tops Revenue Estimates
09:35pm, Wednesday, 06'th May 2020
Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
GBT Reports Recent Business Progress and First Quarter 2020 Financial Results
08:05pm, Wednesday, 06'th May 2020
Achieved Oxbryta® (voxelotor) net revenues of $14.1 million in first full quarter of launch Approximately 1,650 new patient prescriptions for Oxbryta during the first quarter.
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Should You Global Blood (GBT) Ahead of Earnings?
12:45pm, Tuesday, 05'th May 2020
Global Blood (GBT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors o
